On Wednesday, Shares of Amdocs Limited (NASDAQ:DOX), subtract -2.78% and closed at $56.73 in the last trading session. The last trading range of the stock ranges between $54.91 and $57.27. Amdocs (DOX), the leading provider of customer experience solutions, recently declared the availability of its Mobile Financial Services card administration system, which supports service providers across all industries, counting communications, retail and financial services, in launching their own debit or prepaid payment cards. The cards can be linked to a mobile wallet, with stored monetary value, loyalty points or airtime as the source of funds. Customers who don’t have a bank account can use these cards to pay for purchases at retail point of sale terminals, to withdraw cash from an ATM or for online shopping.
Amdocs’ card administration system can be quickly deployed on the cloud as Software as a Service (SaaS), integrating securely with local card-manufacturing companies for card printing and distribution. The system incorporates a back-office administration user interface that manages card specifications, card product definitions and issuer identification number (IIN) ranges. The user interface also offers card ordering workflows with external card printer companies, counting recording of card testing results. Application programming interfaces (APIs) facilitate activation of both physical and virtual cards and their association with stored value accounts, such as mobile wallet and loyalty point accounts. Card numbers issued by the system are validated each time a payment request is processed.
PTC Therapeutics, Inc. (NASDAQ:PTCT), jumped 7.27% and closed at $5.61 in the last trading session. The last trading range of the stock ranges between $5.43 and $5.85. The company’s Market capitalization is $178.53 million with the total Outstanding Shares of 34.32 million. PTC Therapeutics, Inc. (PTCT) recently declared a corporate update and stated financial results for the third quarter ending September 30, 2016.
“For the past 18 years, we have focused noteworthyeffort towards developing Translarna for those affected by Duchenne,” stated Stuart W. Peltz, Ph.D. Chief Executive Officer, PTC Therapeutics, Inc. “Over 400 Duchenne patients have take partd in our clinical trials dating back to 2005 and the vast majority continue to remain on Translarna counting about 130 boys in the United States. With this high compliance rate, we believe these actions speak to the benefit Translarna is providing to patients in the U.S. and around the world. In the E.U., regulatory negotiations continue and we anticipate an opinion from the CHMP before the end of the year. With respect to the U.S., we will continue to escalate our appeal so that we may have the opportunity to have the Translarna NDA submission reviewed by the FDA. Our aim remains to deliver this novel therapy to nonsense mutation Duchenne patients globally.”
ReneSola Ltd. (ADR)(NYSE:SOL), lost -0.346% and closed at $0.840in the last trading session. The last trading range of the stock ranges between $0.75 and $0.86. During the 52-week trading session the minimum price at which share price traded, registered at $0.75 and reached to max level of $1.95. ReneSola Ltd (“ReneSola” or the “Company”) (SOL), a leading fully-integrated solar project developer and provider of energy-efficient products, recently declared that on November 7, 2016, it received notice from the New York Stock Exchange (“NYSE”) that the Company did not meet the NYSE’s price criteria for continued listing standard because the average closing price of the Company’s American Depositary Shares, or ADSs, was less than $1.00 per ADS over a successive 30-trading-day period.
Under NYSE rules, the Company has six months following receipt of the notification to regain compliance with the minimum share price requirement. The Company can regain compliance at any time during the six-month cure period if the Company’s ADSs have a closing share price of at least $1.00 on the last trading day of any calendar month during the period and also has an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period.